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Abstract
Background: Therapeutic plasma exchange (TPE) plays a key role in the management of various diseases, from thrombotic
thrombocytopenic purpura and Goodpasture’s syndrome to cardiac allograft rejection. In many of these disease states
cardiac and inflammatory involvement is common and biomarkers are routinely used for diagnosis or assessment of
therapeutic success. The effect of TPE on biomarkers used in the clinical routine has not been investigated.
Methods: TPE was initiated for established clinical conditions in 21 patients. Troponin T, NT-proBNP, C-reactive protein,
procalcitonin and routine chemistry were drawn before and after TPE, as well as before and after the 2
nd TPE. The total
amount of these markers in the waste bag was also analyzed.
Results: In 21 patients 42 TPEs were performed. The procedure reduced plasma levels of the examined biomarkers: 23% for
NT-proBNP (pre vs. post: 4637610234 ng/l to 356568295 ng/l, p,0.001), 64% for CRP (21.9647.0 mg/l vs. 7.8615.8 mg/l,
p,0.001) and 31% for procalcitonin (0.3961.1 mg/l vs. 0.2760.72 mg/l, p=0.004). TPE also tended to reduce plasma levels of
troponin T by about 14% (60.76175.5 ng/l vs. 52.26141.3 ng/l), however this difference was not statistical significant
(p=0.95). There was a significant correlation between the difference of pre TPE levels to post TPE levels of all examined
biomarkers and the total amount of the removed biomarker in the collected removed plasma.
Conclusions: TPE significantly reduces plasma levels of inflammatory and cardiac biomarkers. Therefore, post TPE levels of
cardiac and inflammatory biomarkers should be viewed with caution.
Citation: Tutarel O, Golla P, Beutel G, Bauersachs J, David S, et al. (2012) Therapeutic Plasma Exchange Decreases Levels of Routinely Used Cardiac and
Inflammatory Biomarkers. PLoS ONE 7(6): e38573. doi:10.1371/journal.pone.0038573
Editor: Alberico Catapano, University of Milan, Italy
Received March 13, 2012; Accepted May 7, 2012; Published June 7, 2012
Copyright:  2012 Tutarel et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Publication costs are covered by the program ‘‘Open Access Publication’’ of the Deutsche Forschungsgemeinsschaft. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: JTK has received research funding from Caridian BCT for an investigator-initiated study with unrestricted research support, i.e. no
influence on the current study. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials. There are no other
competing interests.
* E-mail: kielstein@yahoo.com
. These authors contributed equally to this work.
Introduction
Therapeutic plasma exchange (TPE) is an extracorporeal blood
purification technique that was first described in 1914 [1]. It
removes pathogenic substances such as autoantibodies, lipoproteins
and circulating immune complexes from the plasma [2–4].
According to the 2010 guidelines of the American Society of
Apheresis TPE plays a key role in the management of various
diseases and is the treatment of choice for acute ANCA associated
rapid progressive glomerulonephritis, thrombotic thrombocytope-
nic purpura, Guillan-Barre ´ syndrome, Goodpasture’s syndrome
and cardiac allograft rejection to name a few [3–4]. Most recently
TPE was the mainstay of therapy during the enterohemorrhagic E.
coli associated outbreak of hemolytic uremic syndrome in Germany
[5]. In many of the aforementioned disease states cardiac and
inflammatory involvement is common. Patschan et al. [6] showed
that about one out of fivepatients withthromboticmicroangiopathy
suffers from acute myocardial infarction. Moreover, Dengler et al.
[7] found that acute allograft rejection after human heart
transplantation is often associated with increased serum concentra-
tions of troponin. Despite the pivotal role of biomarkers in the
diagnosis and therapy of heart disease [8,9], the effect of TPE on
circulating biomarkers has not been investigated. Therefore, the
aim of our study was to assess the effect of TPE on the plasma
concentration of cardiac biomarkers and inflammatory markers in
patients undergoing TPE using albumin as replacement fluid. In
addition to the blood levels, the total amount of the removed
biomarker was determined in the collected eliminated plasma.
Materials and Methods
The study was approved by the local ethics committee at the
Hannover Medical School. All patients gave written informed
consent.
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Blood samples for measurement of plasma troponin T, NT-
proBNP, C-reactive protein, procalcitonin and routine chemistry
were drawn before and at the end of the TPE, before the rinse
back of the blood. Also the total amount of the measured
biomarkers in the waste bag was analyzed. All measurements were
done with routine laboratory tests using certified assay methods.
Statistical analysis was performed with SPSS 15.0 and
GraphPad Prism 5. Continuous data were presented as means
6 standard deviation and median + interquartile range (IQR).
Categorical data are presented as counts and proportions.
Comparisons before and after the 1
st and 2
nd TPE as well as
post 1
st TPE levels and pre 2
nd TPE levels were examined using
the Wilcoxon test. For correlation Spearman’s correlation
coefficient was calculated. The significance level was set at
p,0.05.
Results
In a total of 21 patients 42 TPEs were performed. Table 1
shows the clinical characteristics of the study population.
The reduction of the examined biomarkers comparing pre TPE
and post TPE plasma levels was 23% for N-terminal-pro-brain
natriuretic peptide (NT-proBNP) (pre TPE vs. post TPE:
4637610234 ng/l (median 310 ng/l, IQR 1569 ng/l) to
356568295 ng/l (median 219 ng/l, IQR 1168 ng/l), p,0.001),
64% for C-reactive protein (CRP) (21.9647.0 mg/l (median
5.7 mg/l, IQR 13.25 mg/l) vs. 7.8615.8 mg/l (median 1.9 mg/l,
5.6 IQR mg/l), p,0.001) and 31% for procalcitonin
(0.3961.1 mg/l (median 0.08 mg/l, IQR 0.12 mg/l) vs.
0.2760.72 mg/l (median 0.08 mg/l, IQR 0.07 mg/l), p=0.004).
TPE also tended to reduce plasma levels of troponin T by about
14% (60.76175.5 ng/l (median 13.7 ng/l, IQR 33.0 ng/l) vs.
52.26141.3 ng/l (median 14.2 ng/l, IQR 23.6 ng/l), however
this difference was not statistical significant (p=0.95) (Figure 1
and 2).
There was a significant correlation between the difference of pre
TPE to post TPE levels and the total amount of the removed
biomarker in the collected eliminated plasma for NT-proBNP
(r=0.821, p,0.001), troponin T (r=0.694, p,0.001), CRP
(r=0.994, p,0.001) and procalcitonin (r=0.504, p,0.001).
The absolute amount of the removed biomarkers was
15215634269 ng (median 1014 ng, IQR 5289 ng) for NT-
proBNP, 216.66599.7 ng (median 51.5 ng, IQR 118.7 ng) for
troponin T, 46.6697.8 mg (median 10.3 mg, IQR 35.8 mg) for
CRP, and 1.2363.44 mg (median 0.26 mg, IQR 0.43 mg) for
procalcitonin (Figure 1 and 2). Pre and post TPE hematocrit did
not differ (34.265.1% vs. 34.566.0%; p=0.442), excluding
hemoconcentration or -dilution, which could have influenced the
concentration of biomarkers.
The kinetics of the biomarkers were analyzed via a comparison
between pre TPE (pre TPE1) and post TPE (post TPE 1) levels for
the first TPE with the pre TPE levels before the second TPE (pre
TPE 2). The second TPE was performed 2565 hours after the
first. While NT-proBNP increased 1 day after the first TPE (pre
TPE 2 vs. post TPE 1 (4270610097 ng/l (median 284 ng/l, IQR
1470 ng/l) to 383968746 ng/l (median 227 ng/l, IQR 1586 ng/
l)), it was still significantly reduced compared to pre TPE 1 levels
(5003610606 ng/l (median 336 ng/l, IQR 2336 ng/l), p=0.04)
(Figure 3). A different effect was seen for CRP. Pre TPE 2 levels
were higher than post TPE 1 levels (15.3628.8 mg/l (median
6.6 mg/l, IQR 9.8 mg/l) vs. 9.3618.2 mg/l (median 1.5 mg/l,
IQR 9.45 mg/l), p=0.004) and statistically not significant lower
than pre TPE 1 levels (28.5660.0 mg/l (median 3.9 mg/l, IQR
23.6 mg/l), p=0.211) (Figure 3). For procalcitonin and troponin
T no significant difference was observed in the longitudinal
analysis (pre TPE 1 vs. post TPE 1 vs. pre TPE2 for procalcitonin
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Data are expressed as mean6SD or as counts.
doi:10.1371/journal.pone.0038573.t001
Figure 1. Plasma levels of cardiac biomarkers. Pre and post TPE (left axis) and total amount in the waste bag (right axis). A. N-terminal-pro-brain
natriuretic peptide (NT-proBNP); B. troponin T.
doi:10.1371/journal.pone.0038573.g001
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(median 0.07 mg/l, 0.11 IQR mg/l) vs. 0.3560.91 mg/l (median
0.09 mg/l, IQR 0.12 mg/l), and for troponin T 62.36186.4 ng/l
(median 13.8 ng/l, IQR 30.0 ng/l) vs. 55.16154.6 (median
14.8 ng/l, IQR 21.3 ng/l) vs. 59.16168.6 ng/l (median
13.6 ng/l, IQR 34.4 ng/l) (Figure 3).
Discussion
To our knowledge this is the first study evaluating the effect of a
single TPE on cardiac and inflammatory biomarkers and directly
quantifying the amount of these removed substances. We show
that a single TPE can reduce plasma levels of several cardiac and
inflammatory biomarkers (i.e. NT-proBNP, CRP and procalcito-
Figure 2. Plasma levels of inflammatory biomarkers. Pre and post TPE (left axis) and total amount in the waste bag (right axis). A. C-reactive
protein (CRP); B. procalcitonin.
doi:10.1371/journal.pone.0038573.g002
Figure 3. Longitudinal kinetics of the investigated biomarkers. A. N-terminal-pro-brain natriuretic peptide (NT-proBNP); B. troponin T; C. C-
reactive protein (CRP); D. procalcitonin.
doi:10.1371/journal.pone.0038573.g003
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reach statistical significance.
In a recent study, Hershcovici et al. reported their experience
with TPE in 6 patients with severe hyperlipidemia [10]. CRP
levels were significantly reduced. Unfortunately, the authors did
not measure CRP levels in the waste bag. Bektas and colleagues
reported a significant reduction of serum aminotransferases and
bilirubin levels after TPE in patients with liver failure [11]. Even if
data for hematocrit were not reported and amount of the
circulating markers in the waste bag was not analyzed, the
authors suggested hemodilution as a possible mechanism of
biomarker reduction in the plasma. From our own data we can
rule out hemodilution since the hematocrit remained stable. It is
reasonable to assume that TPE removes these biomarkers from the
plasma since there is a significant correlation between the
difference of pre TPE to post TPE levels and the total amount
of the removed biomarker in the collected eliminated plasma. This
demonstrates that the observed reduction is indeed a direct
consequence of TPE-associated removal, rather than (just) an
improvement in the particular disease condition.
Our data are of importance for the interpretation of treatment
success in particular in those diseases in which TPE is frequently
performed. The decrease of CRP or procalcitonin in Goodpasture
syndrome for instance is thought to be associated with a more
favorable outcome [12]. However, our results suggest that TPE
decreases CRP and procalcitonin. Therefore, we should be
cautious when using this marker for the assessment of treatment
effects in cases of Goodpasture syndrome (and probably many
others) in which TPE is part of the treatment.
In up to 20 percent of patients with thrombotic microangiop-
athies acute coronary syndromes are observed [6]. TPE lowers
troponin T levels and could hinder prompt diagnosis in patients
with clinical signs of acute coronary syndrome leading to false
negative diagnosis.
Changes in NT-proBNP levels have been proposed as an
approach to detect rejection in cardiac transplant recipients [13].
Again, TPE is part of the treatment in patients with humoral
rejection [14]. According to our results NT-proBNP levels could
be false low after TPE possibly masking ongoing rejection.
Longitudinal analysis reflecting the kinetics of the biomarkers
after TPE showed that while the reduction in CRP is not
significant after one day, the reduction of NT-proBNP lasts.
A limitation of our study is that albumin was used as
replacement fluid during TPE because fresh frozen plasma would
have interfered with the analysis of the biomarkers. Therefore, our
results are valid for TPE with albumin. Further, underlying
illnesses necessitating TPE spanned a variety of conditions.
Different morbidities may affect the kinetics of the measured
biomarkers. This could lead to an over- or underestimation of the
effects of TPE. In future studies a more homogenous patient group
should be studied and ideally be compared with an untreated
control group.
In conclusion, post TPE levels of cardiac and inflammatory
biomarkers especially NT-proBNP should be viewed with caution.
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